Diabetes Tracker

Target Audience: ,

Clinical Effectiveness
Version: 4.84
Developer: My Net Diary
Review Date: 2016-04-21
Cost: $9.99 (paid only)

Overall App Summary:

Diabetes Tracker by MyNetDiary allows diabetics and those at risk for diabetes mellitus to track and enter data on various health measures that can affect diabetes. These measures pertain to blood glucose, weight, exercise, food intake, and various other health measures. The user may be overwhelmed by all the potential features and the required manual entry of all the data. The company claims that active users lose weight and lower there hemoglobin A1c (blood measure of diabetes), but their specific study results are not reported, nor are proper clinical trials in place to support the app’s effectiveness. This app is very similar to other health apps that allow the user to track many health measures and does not seem to offer a distinguishing or superior feature. This app will appeal to users interested in tracking many health features and do not mind manually entering their data.


App’s Intended Use:

Diabetes Tracker by MyNetDiary is a multi-function application that provides methods for patients with diabetes mellitus to track blood glucose, meals/caloric intake, exercises, medications, and various other health measures. Furthermore, the app claims to have pre-diabetic appeal as well – in addition to being a comprehensive tracker.


Who’s this app most useful for?

This app will be most useful for patients with diabetes mellitus or those at risk for it (e. g. overweight); as well as parents and caregivers.


How should one use it?

This app is best used as a multi-measure journal to track many health measures.


Why should anyone use this app? Is it clinically relevant?

By monitoring the various health measures in this app, the user may be inspired to improve his or her health. By tracking exercise, the user may exercise more. By tracking diet, they may consume less calories. And so on. There are many possibilities, which may overwhelm the user – a lot of manual entry, every day or several times per day.


Is there any published evidence that the app actually works?

The company website claims that “An active user loses 12% of body weight on average…(and an) average self-reported A1C reduction is 1.4%. There are no published clinical trials to support this claim. The concept behind the app is fairly valid in that exercise, weight loss, blood glucose monitoring, diet monitoring, and so forth, are all desirable tools to combat diabetes mellitus.


Regulatory Compliance


What is the most important/ desirable feature of the app?

The most desirable feature is the app’s ability to correlate food intake (input) to blood glucose levels. However, the app is overly complex and there are too many features. An active user would have to be very active on the app to enter all the needed data. This app best serves users who want a lot of data and are happy entering it. This user would benefit from all the potential reports generated, which might inspire him or her to modify behavior and be more healthy.


How is the app’s usability (look and feel; ease of use)?

It’s usability is only satisfactory; the app has a fairly complex interface with many features, none of which are obviously prioritized. Many users would not know where to begin or end with it.


How does this app compare to others in its category?

This app blends into a crowded field of “measure everything” apps; however it’s much more complete in functionality than some of the other apps.


If there’s a paid version, is it worth the upgrade?

This app is paid only and the fee will be worth it to the user who wants to manually record or view a lot of data.


Ayesha Khalid

Ayesha is an ENT surgeon at Harvard Medical School with an MBA in Global Leadership and Innovation from the MIT Sloan School of Management. Ayesha serves on several Boards for medical organizations and is currently on the board of the American Academy of Otolaryngology- Head and Neck Surgery. Ayesha has experience with consulting for private equity firms to evaluate business opportunities in the health IT and medical practice management. She served as Vice-President of Business Development of a digital health start-up out of Johns Hopkins, Doctella. Presently, in addition to clinical practice, Ayes is the Clinician Director for CBIT at the Yale School of Medicine and is curating early stage health IT startups. You can follow Ayesha on Twitter at @ayeshakhalidmd

Conflicts of Interest

Employment: Cambridge Hospital and Harvard Medical School; Yale School of Medicine; Consultant/ Advisor: 480 Biomedical, Stallergenes Greer, Smith and Nephew, Lambay Advisors, Burr Pilgrim Mayer; Ownership: 480 Biomedical, Collective Healthtech, GeoHealth

Adam Cohen

Dr. Adam B. Cohen, a Michigan native, is a neurologist & neuro-ophthalmologist at Massachusetts General Hospital in Boston, Massachusetts, where he is the Neurology Inpatient Medical Director and TeleNeurology Co-Director. He focuses on process innovation, digital health, and improving the efficiency of specialty health care delivery.

Conflicts of Interest:

Employment: Massachusetts General Hospital and Harvard Medical School; Consultant/ Advisor: Decibel Therapeutics, EM Gladiators LLC; Ownership: Expertaj; Research: Academic only; no private funding.

Maulik Majmudar

Dr. Maulik Majmudar is a practicing cardiologist and Associate Director of the Healthcare Transformation Lab at Massachusetts General Hospital; and an Instructor at Harvard Medical School. He lectures at Massachusetts Institute of Technology in areas of healthcare innovation & entrepreneurship, as well as medical device design and development. Dr. Majmudar started his career as a medical student at Northwestern University Feinberg School of Medicine, completed resident training in Internal Medicine at The Johns Hopkins Hospital, and followed by a fellowship in Cardiovascular Medicine at Brigham and Women's Hospital at Harvard Medical School. You can follow him @mmajmudar

Conflicts of Interest:

Employment: Massachusetts General Hospital and Harvard Medical School; Consultant/ Advisor: AliveCor, BioFourmis, Cardiogram, EchoSense, Facebook, HUINNO, MC10, Nokia; Ownership: BioFourmis, Cardiogram, HiLabs, Quanttus; Research: EchoSense, GE Healthcare, MIT.

Leave a Reply

Your email address will not be published. Required fields are marked *